124 related articles for article (PubMed ID: 10670826)
1. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
[TBL] [Abstract][Full Text] [Related]
2. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
[TBL] [Abstract][Full Text] [Related]
3. (N-stearyl, norleucine17)VIPhybrid is a broad spectrum vasoactive intestinal peptide receptor antagonist.
Moody TW; Jensen RT; Fridkin M; Gozes I
J Mol Neurosci; 2002; 18(1-2):29-35. PubMed ID: 11931347
[TBL] [Abstract][Full Text] [Related]
4. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
[TBL] [Abstract][Full Text] [Related]
5. (Stearyl, Norleucine17)VIP hybrid antagonizes VIP receptors on non-small cell lung cancer cells.
Moody TW; Leyton J; Coelho T; Jakowlew S; Takahashi K; Jameison F; Koh M; Fridkin M; Gozes I; Knight M
Life Sci; 1997; 61(17):1657-66. PubMed ID: 9363981
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
[TBL] [Abstract][Full Text] [Related]
7. A vasoactive intestinal peptide antagonist inhibits the growth of glioblastoma cells.
Sharma A; Walters J; Gozes Y; Fridkin M; Brenneman D; Gozes I; Moody TW
J Mol Neurosci; 2001 Dec; 17(3):331-9. PubMed ID: 11859929
[TBL] [Abstract][Full Text] [Related]
8. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
[TBL] [Abstract][Full Text] [Related]
10. VIP receptor antagonists inhibit mammary carcinogenesis in C3(1)SV40T antigen mice.
Moody TW; Dudek J; Zakowicz H; Walters J; Jensen RT; Petricoin E; Couldrey C; Green JE
Life Sci; 2004 Jan; 74(11):1345-57. PubMed ID: 14706566
[TBL] [Abstract][Full Text] [Related]
11. Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers.
Rekasi Z; Varga JL; Schally AV; Halmos G; Armatis P; Groot K; Czompoly T
Endocrinology; 2000 Jun; 141(6):2120-8. PubMed ID: 10830299
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
[TBL] [Abstract][Full Text] [Related]
13. Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.
Balster DA; O'Dorisio MS; Albers AR; Park SK; Qualman SJ
Regul Pept; 2002 Nov; 109(1-3):155-65. PubMed ID: 12409228
[TBL] [Abstract][Full Text] [Related]
14. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
15. Localisation of VIP-binding sites exhibiting properties of VPAC receptors in chromaffin cells of rainbow trout (Oncorhynchus mykiss).
Montpetit CJ; Shahsavarani A; Perry SF
J Exp Biol; 2003 Jun; 206(Pt 11):1917-27. PubMed ID: 12728013
[TBL] [Abstract][Full Text] [Related]
16. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
17. VIP-ellipticine derivatives inhibit the growth of breast cancer cells.
Moody TW; Czerwinski G; Tarasova NI; Michejda CJ
Life Sci; 2002 Jul; 71(9):1005-14. PubMed ID: 12088760
[TBL] [Abstract][Full Text] [Related]
18. (Arg15, Arg21) VIP: evaluation of biological activity and localization to breast cancer tumors.
Moody TW; Leyton J; Unsworth E; John C; Lang L; Eckelman WC
Peptides; 1998; 19(3):585-92. PubMed ID: 9533649
[TBL] [Abstract][Full Text] [Related]
19. Development of selective agonists and antagonists for the human vasoactive intestinal polypeptide VPAC(2) receptor.
Moreno D; Gourlet P; De Neef P; Cnudde J; Waelbroeck M; Robberecht P
Peptides; 2000 Oct; 21(10):1543-9. PubMed ID: 11068102
[TBL] [Abstract][Full Text] [Related]
20. The autocrine regulatory effect of vasoactive intestinal peptide on the growth of human pancreatic carcinoma cells.
Chen Y; Chen Q; Lu G; Fan Z; Zhong S
Chin Med Sci J; 1994 Dec; 9(4):215-9. PubMed ID: 7718859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
